Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Claritin-D

This article was originally published in The Tan Sheet

Executive Summary

Impax Labs granted tentative approval for generic loratadine/pseudoephedrine extended-release tablets (Schering-Plough's Claritin-D 12- and 24-Hour) on May 29 and May 24, respectively. Hayward, Calif.-based company believes it was first to file for generic 12-hour formulation. Impax, a defendant in Schering's ongoing loratadine patent litigation, also has a pending ANDA for Claritin Reditabs. In December, Impax entered into an agreement granting Novartis Consumer Health exclusive rights to market an OTC generic version of Claritin to be supplied by Impax, which is in discussions with potential OTC partners for two additional generic loratadine formulations. Novartis' Geneva Pharmaceuticals is believed to be first to file for the loratadine 10 mg tablet dosage form...

You may also be interested in...



Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.

Horizon's Teprotumumab Breezes Through US FDA Adcom, But Safety Questions Remain

Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.

Topics

UsernamePublicRestriction

Register

PS094119

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel